Letter to the editor submitted in response to “efficacy and safety of imiquimod 5% cream for basal cell carcinoma: a Meta-analysis of randomised controlled trial”

Emma AxonCentre of Evidence Based Dermatology, University of Nottingham, Nottingham, UKCorrespondence[email protected]

https://orcid.org/0000-0002-3246-9968

Douglas J. GrindlayCentre of Evidence Based Dermatology, University of Nottingham, Nottingham, UK

https://orcid.org/0000-0002-0992-7182

References

Jia HX, He YL. Efficacy and safety of imiquimod 5% cream for basal cell carcinoma: a meta-analysis of randomized controlled trial. J Dermatolog Treat. 2019 [cited Jul 22]; [8 p.]. DOI:10.1080/09546634.2019.1638883
PubMed Web of Science ®Google Scholar
Bath-Hextall F, Ozolins M, Armstrong SJ, et al. Surgical excision versus imiquimod 5% cream for nodular and superficial basal-cell carcinoma (SINS): a multicentre, non-inferiority, randomised controlled trial. Lancet Oncol. 2014;15:96–105.
PubMed Web of Science ®Google Scholar
Williams HC, Bath-Hextall F, Ozolins M, et al. Surgery versus 5% imiquimod for nodular and superficial basal cell carcinoma: 5-year results of the SINS randomized controlled trial. J Invest Dermatol. 2017;137:614–619.
PubMed Web of Science ®Google Scholar
Beutner KR, Geisse JK, Helman D, et al. Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream. J Am Acad Dermatol. 1999;41:1002–1007.
PubMed Web of Science ®Google Scholar
Higgins J, Green S. (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]: The Cochrane Collaboration. Available from www.handbook.cochrane.org.
Google Scholar
Nankervis H. Correspondence in relation to “meta-analysis on the comparison between two topical calcineurin inhibitors in atopic dermatitis. J Dermatol. 2012;39:1111–1112.
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Letter to the editor submitted in response to “efficacy and safety of imiquimod 5% cream for basal cell carcinoma: a Meta-analysis of randomised controlled trial”

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Letter to the editor submitted in response to “efficacy and safety of imiquimod 5% cream for basal cell carcinoma: a Meta-analysis of randomised controlled trial”

References

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date